AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side effects. The company is in the preclinical stage.